PTGX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
213.5M
+278.7%
56.4M
+657.9%
7.4M
+57.8%
4.7M
-15.0%
5.5M
Cost of Revenue
0
0
0
0
0
Gross Profit
213.5M
+278.7%
56.4M
+657.9%
7.4M
+57.8%
4.7M
-15.0%
5.5M
Operating Expenses
54.7M
-8.8%
60.0M
+3.8%
57.8M
+13.0%
51.1M
+7.5%
47.6M
R&D
42.1M
-10.0%
46.7M
+0.8%
46.4M
+15.9%
40.0M
+8.0%
37.0M
SG&A
12.6M
-4.7%
13.3M
+16.1%
11.4M
+2.7%
11.1M
+5.5%
10.6M
Operating Income
158.8M
+4452.1%
-3648000
+92.8%
-50355000
-8.5%
-46421000
-10.4%
-42041000
EBITDA
158.8M
+4998.7%
-3241000
+93.5%
-49979000
-8.5%
-46060000
-9.6%
-42041000
Net Income
162.8M
+4204.8%
3.8M
+108.5%
-44384000
-12.8%
-39339000
-13.1%
-34771000
EPS (Basic)
$2.47
+4016.7%
$0.06
+108.7%
$-0.69
-11.3%
$-0.62
-12.7%
$-0.55
EPS (Diluted)
$2.29
+4480.0%
$0.05
+107.2%
$-0.69
-11.3%
$-0.62
-12.7%
$-0.55
Shares (Diluted)
71.0M
+0.7%
70.5M
+10.1%
64.0M
+0.4%
63.8M
+0.4%
63.5M
Protagonist Therapeutics (PTGX) โ€” Financials